Norges Bank Allovir, Inc. Transaction History

Norges Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$20.81 - $45.5 $1.04 Million - $2.28 Million	-50,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$23.94 - $46.81 $1.2 Million - $2.34 Million	50,000 New	50,000 $1.92 Million
Q4 2020 Feb 10, 2021	SELL	$23.94 - $46.81 $1.2 Million - $2.34 Million	-50,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$21.05 - $42.7 $1.05 Million - $2.14 Million	50,000 New	50,000 $1.38 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $37.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.